A dose‐block randomized, double‐blind, placebo‐controlled, single ascending dose study assessing the safety and pharmacokinetics of Hy209 in healthy volunteers
Latest Information Update: 22 Apr 2021
At a glance
- Drugs Taurodeoxycholic-acid (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; First in man; Pharmacokinetics
- 22 Apr 2021 New trial record
- 17 Mar 2021 Results presented at the 122nd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics